Key result
Two-dose SARS-CoV-2 mRNA vaccine series undergoes evaluation for antibody response in solid organ transplant recipients.
Why the study?
Does a 2-dose SARS-CoV-2 mRNA vaccine series improve antibody response in solid organ transplant recipients?
Does a 2-dose SARS-CoV-2 mRNA vaccine series improve antibody response in solid organ transplant recipients?
This study evaluates the antibody response to a 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients.
Provides initial cohort data on vaccine immunogenicity in transplant recipients; leaves open efficacy against infection and optimal regimens.
This follow-up study measures the antibody response following the second dose of SARS-CoV-2 mRNA vaccine in recipients of solid organ transplants.
No takes yet. Share an insight, caveat, or question.
Boyarsky et al. (2021) studied this question. A 2-dose SARS-CoV-2 mRNA vaccine series was evaluated for antibody response in solid organ transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: